We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 24, 2021

LY2780301, a p70S6K/AKT Inhibitor, in Combination With Weekly Paclitaxel in HER2-Negative Advanced Breast Cancer

European Journal of Cancer


Additional Info

European Journal of Cancer
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients
Eur. J. Cancer 2021 Nov 12;159(xx)205-214, C Vicier, P Sfumato, N Isambert, F Dalenc, M Robert, C Levy, K Rezai, M Provansal, J Adélaïde, S Garnier, A Guille, N Carbuccia, C Popovici, E Charafe-Jauffret, M Chaffanet, D Birnbaum, J Pakradouni, F Bertucci, JM Boher, R Sabatier, A Gonçalves

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading